---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-019330"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2022-10-06T23:59:59+00:00"
generated_at: "2026-06-23T05:07:00.933404+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cyclerion cuts 45% of workforce, focuses on mitochondrial disease after positive MELAS data

## Summary
- Workforce reduced by ~45% (13 employees) in Q4 2022 to align with mitochondrial disease strategy.
- Estimated severance charge of ~$1.9M in Q4 2022; expects annual cash savings of ~$4.1M.
- Plans to meet with FDA in Q4 2022 to discuss CY6463 development path for MELAS.
- ADv study enrollment capped; data expected H1 2023; CIAS program CY3018 to seek partnership.
- Will out-license olinciguat and praliciguat; praliciguat already licensed to Akebia for milestones/royalties.

## SEC filing metadata
- accession: 0000950170-22-019330
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2022-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000095017022019330/0000950170-22-019330-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000095017022019330/cycn-20221006.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-019330
- JSON: https://secwatch.observer/filing/0000950170-22-019330.json
- Plain text: https://secwatch.observer/filing/0000950170-22-019330.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.